Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
01 jul 2014 - 07:30
Statutaire naam
Galapagos NV
Titel
Galapagos initiates Phase 1 study with GLPG1690, triggering €6.6 M milestone in the alliance with Janssen Pharmaceutica NV
Bericht
Mechelen, Belgium; 1 July 2014 - Galapagos NV (Euronext: GLPG) announced today that GLPG1690, a first-in-class molecule aimed at treating pulmonary diseases, has been dosed in a Phase 1 First-in-Human study. Galapagos will receive a €6.6 million milestone payment from Janssen Pharmaceutica NV for this achievement.
Datum laatste update: 26 juni 2026